There are currently 120 clinical trials in Pensacola, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Nemours Children's Clinic - Pensacola, Sacred Heart Hospital, Retina Specialty Institute and Sacred Heart Cancer Center at Sacred Heart Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620
Recruiting
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic chang... Read More
Gender:
All
Ages:
Between 12 months and 21 years
Trial Updated:
04/27/2024
Locations: Nemours Children's Clinic - Pensacola, Pensacola, Florida +1 locations
Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Register for Updates
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
NCT04444921
Recruiting
This phase 3 trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2024
Locations: Sacred Heart Hospital, Pensacola, Florida
Conditions: Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Stage IV Anal Cancer AJCC v8, Unresectable Anal Squamous Cell Carcinoma, Anal Basaloid Squamous Cell Carcinoma
Register for Updates
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652
Recruiting
This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
Between 12 months and 21 years
Trial Updated:
04/27/2024
Locations: Nemours Children's Clinic - Pensacola, Pensacola, Florida
Conditions: Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Wilms Tumor, Malignant Solid Neoplasm, Recurrent Soft Tissue Sarcoma, Refractory Soft Tissue Sarcoma, Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor
Register for Updates
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409
Recruiting
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs... Read More
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
04/27/2024
Locations: Sacred Heart Hospital, Pensacola, Florida
Conditions: Low Grade Glioma, Low Grade Astrocytoma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
Register for Updates
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT03598257
Recruiting
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2024
Locations: Sacred Heart Hospital, Pensacola, Florida
Conditions: Breast Inflammatory Carcinoma
Register for Updates
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
NCT05254834
Recruiting
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
Gender:
All
Ages:
30 years and above
Trial Updated:
04/26/2024
Locations: Ascension Sacred Heart, Pensacola, Florida
Conditions: Cancer
Register for Updates
Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT04704921
Recruiting
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
04/25/2024
Locations: Retina Specialty Institute - Pensacola, Pensacola, Florida
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV
Register for Updates
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT05839041
Recruiting
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
04/25/2024
Locations: Retina Specialty Institute, Pensacola, Florida
Conditions: Geographic Atrophy of the Macula, Macular Degeneration
Register for Updates
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
NCT05550207
Recruiting
This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Clinical Research Site, Pensacola, Florida
Conditions: Migraine
Register for Updates
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747
Recruiting
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/24/2024
Locations: Baptist Health Care, Pensacola, Florida +1 locations
Conditions: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Register for Updates
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05917509
Recruiting
This is a multicentre study carried out in participants living with human immunodeficiency virus type 1 (HIV-1) who have not previously been treated with any antiretroviral therapies. The study will investigate two 2-drug regimens for the treatment of HIV-1: a fixed-dose combination oral tablet of dolutegravir/lamivudine (DTG/3TC) and cabotegravir plus rilpivirine long-acting agents (CAB + RPV LA). All participants will initially receive DTG/3TC once daily, and once virologic suppression is atta... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: GSK Investigational Site, Pensacola, Florida
Conditions: HIV Infections
Register for Updates
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Cardiology Consultants, Pensacola, Florida
Conditions: Atrial Fibrillation
Register for Updates